Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays
Open Access
- 20 August 2010
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 101 (9) , 2005-2010
Abstract
Treatment of CML with the tyrosine kinase inhibitor (TKI) imatinib mesylate results in the emergence of point mutations within the kinase domain (KD) of the BCR‐ABL1 fusion transcript. The introduction of next‐generation TKIs that can overcome the effects of some BCR‐ABL1 KD mutations requires quantitative mutation profiling methods to assess responses. We report the design and validation of such quantitative assays, using pyrosequencing and mutation‐specific RT‐PCR techniques, to allow sequential monitoring and illustrate their use in tracking specific KD mutations (e.g. G250E, T315I, and M351T) following changes in therapy. Pyrosequencing and mutation‐specific RT‐PCR allows sequential monitoring of specific mutations and identification of rapid clonal shifts in response to kinase inhibitor therapy in CML. Rapid reselection of TKI‐resistant clones occurs following therapy switch in CML. (Cancer Sci 2010)Keywords
This publication has 15 references indexed in Scilit:
- Dasatinib for the treatment of Philadelphia chromosome-positive leukaemiasExpert Opinion on Investigational Drugs, 2007
- Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid LeukemiaClinical Cancer Research, 2006
- MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutationBlood, 2006
- Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylateLeukemia, 2006
- TaqMan® Reverse Transcriptase-Polymerase Chain Reaction Coupled With Capillary Electrophoresis for Quantification and Identification of bcr-abl Transcript Type2006
- The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinibLeukemia, 2006
- Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib MesylateClinical Cancer Research, 2005
- Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single centerCancer, 2005
- High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinibThe Hematology Journal, 2004
- Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisBlood, 2003